Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
42.12
-0.17 (-0.40%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Crinetics Pharmaceuticals Revenue
In the year 2023, Crinetics Pharmaceuticals had annual revenue of $4.01M, a decrease of -15.28%.
Revenue (ttm)
$4.01M
Revenue Growth
-15.28%
P/S Ratio
817.94
Revenue / Employee
$13,838
Employees
290
Market Cap
3.28B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.01M | -724.00K | -15.28% |
Dec 31, 2022 | 4.74M | 3.66M | 339.42% |
Dec 31, 2021 | 1.08M | 1.01M | 1,418.31% |
Dec 31, 2020 | 71.00K | -1.12M | -94.05% |
Dec 31, 2019 | 1.19M | -1.24M | -50.86% |
Dec 31, 2018 | 2.43M | 383.00K | 18.73% |
Dec 31, 2017 | 2.05M | 1.46M | 247.20% |
Dec 31, 2016 | 589.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.76B |
Oscar Health | 5.86B |
Fortrea Holdings | 3.11B |
Evolent Health | 1.96B |
Sotera Health Company | 1.05B |
10x Genomics | 618.73M |
Axonics | 366.38M |
Axsome Therapeutics | 270.60M |
CRNX News
- 15 days ago - Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study - Reuters
- 5 weeks ago - Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients - GlobeNewsWire
- 6 weeks ago - Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire